Related Experiment Video
Updated: Mar 15, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers
Ahmed Z Gad1, Shahenda El-Naggar2, Nabil Ahmed3
1Basic Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt; Biotechnology Program, School of Sciences and Engineering, The American University in Cairo, New Cairo, Egypt.
Chimeric antigen receptor (CAR) T cell therapy shows promise for solid tumors, but challenges like the tumor microenvironment and personalized production hinder widespread use. Innovative strategies are emerging to overcome these obstacles for effective cancer treatment development.
Area of Science:
- Immunotherapy
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cell therapy has shown success in hematologic malignancies.
- Solid tumors represent a significant unmet medical need and a large market opportunity for cancer therapies.
Purpose of the Study:
- To highlight the challenges in developing CAR T cell therapy for solid tumors.
- To discuss innovative strategies for overcoming these challenges.
Main Methods:
- Review of current literature on CAR T cell therapy in solid tumors.
- Analysis of challenges including tumor microenvironment, antigen diversity, and stem cell populations.
- Exploration of emerging innovative approaches.
Main Results:
- CAR T cell therapy faces significant hurdles in solid tumors compared to blood cancers.
- The tumor microenvironment, antigen variability, and stem cell persistence pose major obstacles.
- Novel strategies are being developed to enhance CAR T cell efficacy in solid tumors.
Conclusions:
- Overcoming the unique challenges of solid tumors is crucial for advancing CAR T cell therapy.
- A realistic understanding of these challenges is essential for pragmatic drug discovery and development.
- Innovative approaches offer a promising path toward effective solid tumor immunotherapies.
